Guangzhou Wondfo Biotech Co Ltd

Wondfo Biotech released its 2026 interim report, with net profit attributable to the parent company at 123 million yuan, down 35.24% from the same period last year. Total operating revenue was 1.039 billion yuan, down 16.63% year-on-year. Net cash inflow from operating activities was 424 million yuan. The latest gross margin was 63.53%, ROE was 2.25%, and diluted earnings per share was 0.26 yuan. The company had 40,400 shareholders, and the top ten shareholders held 47.61% of the total share capital.

Wondfo Biotech shares have fallen to a new low. As of the close on July 24, the stock ended at 15.69 yuan per share, after touching an intraday low of 15.66 yuan, a recent trough. The latest total market capitalization stands at 7.344 billion yuan, down 72 percent from its peak. The company's 2025 annual report shows revenue of 2.087 billion yuan, a year-on-year decline of 31.91 percent, and a net loss attributable to the parent of 63.02 million yuan, marking its first loss in the ten years since listing. The company attributed the sharp decline in performance mainly to deep industry adjustments, policies such as centralized procurement and DRG/DIP payment models suppressing demand and prices, as well as internal factors like adjustments to sales value-added tax rates, proactive divestiture of low-profit businesses, and strategic emerging businesses still in the investment phase. Despite the poor results, the company stated that new businesses such as tube-based chemiluminescence have made progress, its core competitiveness has not undergone any material adverse changes, and there is no significant risk to its ability to continue as a going concern.